Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumorsRobert Svensson, Peter J. Tummino, Scott Boiko et al.|Cancer Research|2025Cited by 5
Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC).David A. Braun, David Sommerhalder, Kurt C. Demel et al.|Journal of Clinical Oncology|2025Cited by 1
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A. Braun, David Sommerhalder, Julio Peguero et al.|Cell Reports Medicine|2026Cited by 1
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumorsScott Boiko, Robert Svensson, Di Li et al.|European Journal of Cancer|2024Cited by 0